The evaluation of clinical efficacy and safety of polymyxin B in treatment of senile patients with hospital-acquired pneumonia caused by carbapenem-resistant bacteria
10.11855/j.issn.0577-7402.2020.12.11
- VernacularTitle:多黏菌素B对碳青霉烯类耐药菌医院获得性高龄肺炎患者的临床疗效与安全性评价
- Author:
Jiong-He WU
1
;
Ting-Ting LIU
;
Ya-Ping YUAN
;
Chao WANG
;
Xiang-Qun FANG
;
Hong-Xia LI
Author Information
1. 解放军医学院,北京 100853;解放军总医院第二医学中心呼吸与危重症医学科,北京 100853
- Keywords:
polymyxin B;
tigecycline;
carbapenem-resistant bacteria;
hospital-acquired pneumonia
- From:
Medical Journal of Chinese People's Liberation Army
2020;45(12):1277-1281
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and safety of polymyxin B and tigecycline in treatment of carbapenem-resistant pneumonia in elderly patients.Methods This retrospective review involved 44 patients(≥85 years old)from January 2017 to December 2019.All the patients received meropenem in combination with polymyxin B or tigecycline divided into two groups.Group-wise general conditions,clinical efficacy,prognosis and adverse events were analyzed and compared,accordingly.Results A total of 20 patients in the polymyxin B group and 24 patients in the tigecycline group were included.The effective rate,bacterial clearance rate and thirty-day mortality of polymyxin B group were 65.0%,30.0%and 25.0%respectively,with no significant difference from tigecycline group(58.3%,20.8%and 20.8%)(P>0.05).Compared with tigecycline group,the elevated bilirubin incidence in polymyxin B group was significantly lower(10.0%vs.41.7%,P<0.05),but the changes of the procalcitonin[0.35(0.12,0.52)vs.0.07(0.01,0.13),P<0.05]and the skin pigmentation incidence(35.0%vs.0%,P<0.05)were higher.Other outcomes had no significant difference between two groups(P>0.05).Conclusion We found no significant difference in efficacy and thirty-day mortality between two groups.This study found for the first time that light may play a role in promoting skin pigmentation induced by polymyxin B.
